Flagship’s Pronutria Emerges to Make Medicines and Medical Foods

Flagship’s Pronutria Emerges to Make Medicines and Medical Foods

October 22, 2013

Luke Timmerman--Sometimes there may be good protein drugs lurking in your lunch and you just don’t know it. There may be a business in there, too.

Flagship VentureLabs™ Launches Pronutria to Prevent and Treat Diseases with Novel Protein Nutrients

Flagship VentureLabs™ Launches Pronutria to Prevent and Treat Diseases with Novel Protein Nutrients

October 22, 2013

Company Appoints Industry Veteran Robert Connelly as CEO

T2 Biosystems Announces Publication of Data Demonstrating T2Candida® Identifies Candida Significantly Faster than Current Methods

T2 Biosystems Announces Publication of Data Demonstrating T2Candida® Identifies Candida Significantly Faster than Current Methods

October 17, 2013

--Direct Detection and Species Identification from Whole Blood Provides Results in Approximately Three Hours vs. an Average of Greater Than 3 Days for the Current Gold Standard, Blood Culture--

-Limit of Detection as Low as 1 CFU/mL-

Moderna Therapeutics Announces Expansion to New Headquarters and Laboratories at 200 Tech Square

Moderna Therapeutics Announces Expansion to New Headquarters and Laboratories at 200 Tech Square

October 17, 2013

CAMBRIDGE, Mass., Oct. 17, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announces today the expansion of their headquarters to Technology Square in Cambridge, MA. With the addition of the new space, Moderna will have up to 100 full-time employees at two locations by the end of 2013.

(Photo: http://photos.prnewswire.com/prnh/20131017/NE99031)

Quanterix Announces Key Patents Issued for Simoa Platform

Quanterix Announces Key Patents Issued for Simoa Platform

October 16, 2013

Lexington, Mass. – October 16, 2013 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that it has continued to build its patent portfolio with the issuance of three key patents for its Simoa platform.

TARIS Biomedical® Enters Research Collaboration with AstraZeneca for Improved Bladder Cancer Treatments

TARIS Biomedical® Enters Research Collaboration with AstraZeneca for Improved Bladder Cancer Treatments

October 16, 2013

TARIS Biomedical® Enters Research Collaboration with AstraZeneca

for Improved Bladder Cancer Treatments

DARPA Awards Moderna Therapeutics A Grant For Up To $25 Million To Develop Messenger RNA Therapeutics™

DARPA Awards Moderna Therapeutics A Grant For Up To $25 Million To Develop Messenger RNA Therapeutics™

October 2, 2013

Research to focus on antibody production for immune defense

BG Medicine Announces Preliminary Decision by CMS on Reconsideration of Reimbursement for BGM Galectin-3 Test

BG Medicine Announces Preliminary Decision by CMS on Reconsideration of Reimbursement for BGM Galectin-3 Test

September 30, 2013

WALTHAM, Mass., Sept. 30, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have made a preliminary decision to set the Medicare payment rate for the Company's BGM Galectin-3(R) test at the amount of a cross walked test whose 2013 national limitation amount is $30.24, subject to a final determination by CMS by year-end 2013. The new payment rate, if finalized, will replace the BGM Galectin-3(R) test's national limitation amount of $17.80 that was effective in 2013.

Agios Pharmaceuticals Appoints Paul J. Clancy to Its Board of Directors

Agios Pharmaceuticals Appoints Paul J. Clancy to Its Board of Directors

September 26, 2013

CAMBRIDGE, Mass., Sep 26, 2013 (BUSINESS WIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced the addition of Paul J. Clancy, executive vice president and chief financial officer at Biogen Idec, to the company's board of directors.

Novomer Catalytic Process Using Waste CO2 and Shale Gas Targets $20 Billion Market and up to 110% Carbon Footprint Reduction

Novomer Catalytic Process Using Waste CO2 and Shale Gas Targets $20 Billion Market and up to 110% Carbon Footprint Reduction

September 24, 2013

DoE Grant and New Partnership Fuel Potential to Rejuvenate US Global Chemical Market Leadership; "Drop in" Chemical Market Replacements to Reach Commercial Scale in 2017